Tyme Technologies, Inc. entered a new research collaboration with NYU Langone Health to advance the development of innovative treatments for patients with metastatic cancers, including pancreatic cancer. 
 
The broad collaboration will examine the effects of TYME’s cancer metabolism-based therapy, SM-88, and each of the components of MPS (methoxsalen, phenytoin, and sirolimus) on primary pancreatic cancer cell lines, patient-derived pancreatic cancer organoids as well as specialized mouse xenograft models.  The studies will evaluate the potential of SM-88 in combination with standard approved cancer therapies, with a goal to identify optimal synergistic combinations with SM-88 for future development in metastatic cancers. 
 
“We are excited to collaborate on this new effort to help uncover key findings about how specific biomarkers may help slow the development of certain cancer types,” said Diane Simeone, MD, Director of the Pancreatic Cancer Center at NYU Langone Health’s Perlmutter Cancer Center and Lead Principle Investigator for the Pancreatic Cancer Network’s Precision Promise trials.
 
“We believe our translational research can help affect future development of SM-88 and broaden our understanding of this novel approach by targeting cancer metabolism.”
 
“TYME is focused on advancing SM-88 for cancer patients where the unmet medical need is greatest,” said Jonathan Eckard, Ph.D. and Chief Business Officer for Tyme Technologies, Inc. “We are very excited to work on this project with someone as accomplished as Dr. Simeone both in research, and in the clinic as the principle investigator in Precision Promise.”